New data for KSI-101 from the APEX study reinforce its clinically meaningful vision gains and rapid retinal drying in macular edema secondary to inflammation (MESI)
X
Bispecific trap-antibody inhibiting interleukin-6 and vascular endothelial growth factor (KSI-101): first-time results from the Phase 1b APEX Study in patients with macular edema secondary to inflammation (MESI)
